Log in with your email address username.


[Correspondence] ANTARCTIC: platelet function testing to adjust therapy – Authors’ reply

We thank Paul Gurbel and colleagues for their interest in our randomised ANTARCTIC study,1 but we think they have wrongly interpreted both the design and the results of the study. Their statement corresponds neither to the hypothesis nor to the primary endpoint of the study. We wish to underscore that the ANTARCTIC study was not a comparison between prasugrel and clopidogrel, that bleeding was not the primary endpoint, that the study never tested switching from prasugrel to clopidogrel, and that 5 mg is not a low dose but the approved dose of prasugrel for the elderly.